Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GAO examines food import safety gaps

This article was originally published in The Tan Sheet

Executive Summary

A lack of coordination between the agencies that oversee imported food could allow high-risk foods to enter domestic commerce, says a Government Accountability Office 1report released Oct. 14. Gaps arise in part because FDA, the Department of Agriculture's Food Safety Inspection Service and the Department of Homeland Security's Customs and Border Protection division do not have fully interoperable computer systems, GAO says. Additionally, FDA has limited authority to ensure importer compliance and does not assign unique identification numbers to manufacturers, making it difficult to target past violators, the report notes. FDA's response to the report points out the pending Food Safety Enhancement Act, H.R. 2749, would authorize the agency to institute a system of unique numerical identifiers for food firms (2"The Tan Sheet" Sept. 21, 2009)

You may also be interested in...

FDA Stresses Preventive Food Safety As Senate Readies To Move Legislation

FDA is preparing to extend preventive approaches to all food safety areas as the Senate elevates the priority of related legislation

UK Set For January Brexit After Conservatives Win Election

The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.

Dainippon, SanBio Call Time On Stroke Cell Therapy Alliance

Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts